Tzeng E, Shears L L, Robbins P D, Pitt B R, Geller D A, Watkins S C, Simmons R L, Billiar T R
Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Mol Med. 1996 Mar;2(2):211-25.
Nitric oxide (NO) has been shown to decrease myointimal hyperplasia in injured blood vessels. We hypothesize inducible No synthase (iNOS) gene transfer even at low efficiency will provide adequate local no production to achieve this goal.
A retroviral vector containing the human iNOS cDNA (DFGiNOS) was used to transfer the iNOS gene into vascular cells and isolated blood vessels to answer the following questions: can vascular endothelial and smooth muscle cells support iNOS activity and will low efficiency iNOS gene transfer suppress myointimal hyperplasia in injured porcine arteries?
DFGiNOS-infected sheep pulmonary artery endothelial cells (SPAEC) expressed significant iNOS mRNA and protein, releasing nitrite levels of 155.0 +/- 10.7 nmol/mg protein/24 h vs. 5.5 +/- 1.1 by control cells. Transduced rat smooth muscle cells (RSMC) also expressed abundant iNOS mRNA and protein, but, in contrast to SPAEC, NO synthesis was dependent on exogenous tetrahydrobiopterin (BH4) (291.8 +/- 10.4 nmol nitrite/mg protein/24 hr with BH4, 37.7 +/- 2.6 without BH4). Only porcine arteries infected with DFGiNOS following balloon injury exhibited a 3-fold increase in total NO synthesis and a 15-fold increase in cGMP levels over control vessels in a BH4 dependent fashion, despite only a 1% gene transfer efficiency. Transfer of iNOS completely prevented the 53% increase in myointimal thickness induced by balloon catheter injury; the administration of a NOS inhibitor reversed this effect.
These in vitro findings suggest that vascular iNOS gene transfer may be feasible. Furthermore, a low gene transfer efficiency may be sufficient to inhibit myointimal hyperplasia following arterial balloon injury, although a source of BH4 may be required.
一氧化氮(NO)已被证明可减少受损血管中的肌内膜增生。我们推测,即使诱导型一氧化氮合酶(iNOS)基因转移效率很低,也能产生足够的局部NO以实现这一目标。
使用携带人iNOS cDNA的逆转录病毒载体(DFGiNOS)将iNOS基因导入血管细胞和分离的血管,以回答以下问题:血管内皮细胞和平滑肌细胞能否支持iNOS活性,低效率的iNOS基因转移能否抑制受损猪动脉中的肌内膜增生?
DFGiNOS感染的绵羊肺动脉内皮细胞(SPAEC)表达了显著的iNOS mRNA和蛋白,释放的亚硝酸盐水平为155.0±10.7 nmol/mg蛋白/24小时,而对照细胞为5.5±1.1。转导的大鼠平滑肌细胞(RSMC)也表达了丰富的iNOS mRNA和蛋白,但与SPAEC不同,NO合成依赖于外源性四氢生物蝶呤(BH4)(有BH4时为291.8±10.4 nmol亚硝酸盐/mg蛋白/24小时,无BH4时为37.7±2.6)。尽管基因转移效率仅为1%,但在球囊损伤后仅感染DFGiNOS的猪动脉在BH4依赖的方式下,总NO合成增加了3倍,cGMP水平增加了15倍。iNOS的转移完全阻止了球囊导管损伤诱导的肌内膜厚度增加53%;给予NOS抑制剂可逆转这种效应。
这些体外研究结果表明,血管iNOS基因转移可能是可行的。此外,尽管可能需要BH4来源,但低基因转移效率可能足以抑制动脉球囊损伤后的肌内膜增生。